Dendreon Completes Construction of New Jersey Manufacturing Facility

03-Aug-2006 - Dendreon Corporation has completed the initial build-out of its New Jersey manufacturing facility. This state-of-the art facility has the capacity to support clinical processes and future anticipated commercial needs for PROVENGE® (sipuleucel-T), the Company's investigational active cellular ...

Dendreon research shows promising activity of Provenge in combination with Avastin

09-Jun-2006 - Dendreon Corporation announced that the results from a National Cancer Institute (NCI)-sponsored Phase 2 study of its PROVENGE® (sipuleucel-T) active cellular immunotherapy for prostate cancer in combination with Avastin® (bevacizumab) have been published in 'Cancer'. The research which was ...

Dendreon Names Ernest Bognar General Manager of Hanover, NJ Manufacturing Facility

09-Mar-2006 - Dendreon Corporation announced that it named Ernest A. Bognar general manager of the Company's new manufacturing facility in Hanover, New Jersey. Dendreon is currently developing this facility to meet the anticipated clinical and commercial manufacturing needs for PROVENGE® (sipuleucel-T) and its ...

Diosynth Biotechnology enters long-term commercial supply agreement with Dendreon

06-Mar-2006 - Diosynth Biotechnology announced that it has entered into a long-term commercial supply agreement with Dendreon Corporation for the manufacture of the recombinant antigen component of PROVENGE (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for prostate cancer. The ...

Dendreon Announces Strategic Realignment to Focus on PROVENGE BLA and Commercialization

24-Jan-2006 - Dendreon Corporation announced the Company has realigned its resources to focus on advancing PROVENGE® (sipuleucel-T), its lead investigational active cellular immunotherapy for the treatment of prostate cancer, toward the market as expeditiously as possible. In addition, Michelle Burris, senior ...

Dendreon Announces Plans to Submit Application for FDA Approval of Provenge for the Treatment of Advanced Prostate Cancer

16-Sep-2005 - Dendreon Corporation announced plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to market Provenge®, the Company's investigational immunotherapy for the treatment of advanced prostate cancer. This decision follows a recent pre-BLA meeting in ...

Dendreon Announces Senior Management Change

14-Jun-2005 - Dendreon Corporation announced Martin A. Simonetti will step down as senior vice president of finance, chief financial officer and treasurer to spend more time with his family and to eventually pursue opportunities to lead a biotechnology company. This change will be effective in the third ...

Dendreon utilizes pervasive antigen telomerase in new cancer immunotherapy

Preclinical results show significant survival benefit

12-May-2003 - Dendreon Corporation today announced it will present research highlighting the application of the company's new immunotherapy technology to the widely expressed cancer antigen, telomerase. Results of preclinical animal studies have demonstrated that the approach is capable of inducing tumor ...

Dendreon presents promising preclinical results from new technology for cancer immunotherapy

25-Apr-2003 - Dendreon Corporation today presents data for the first time relating to a new immunotherapy technology that allows for the selection of any gene as a target for cancer immunotherapy. In preclinical animal testing to date, this approach has provided up to 100 percent protection from developing ...

Dendreon Corporation and Genentech to Collaborate on Trp-p8 Gene Platform

Potential Value of Deal Over $110 Million

15-Aug-2002 - Seattle, WA (August 13, 2002) – Dendreon Corporation today announced a collaboration with Genentech, Inc. for the research, development and commercialization of products derived from Dendreon’s Trp-p8 gene platform. The agreement concerns the development of monoclonal antibodies, small molecules ...